share_log

HC Wainwright & Co. Initiates Coverage On Arcutis Biotherapeutics With Buy Rating, Announces Price Target of $19

Benzinga ·  Dec 30, 2024 19:54  · Ratings

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces Price Target of $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment